- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC mum on new product news
Nuclear medicine vendor ADAC Laboratories (Hall B, #6711) is promising a new product announcement for the meeting but is planning to keep the news to itself until the show. One new product the Milpitas, CA-based company is talking about is WebView, a
Nuclear medicine vendor ADAC Laboratories (Hall B, #6711) is promising a new product announcement for the meeting but is planning to keep the news to itself until the show. One new product the Milpitas, CA-based company is talking about is WebView, a work-in-progress workstation that enables physicians to interpret and process images in their departments, homes, or offices.
General-purpose and specialized SPECT and cardiac displays have been built into WebView. In addition to nuclear medicine studies, WebView supports multimodality images via the DICOM 3.0 standard. The software runs on Windows NT and Windows 95 operating systems.
ADAC will also discuss MCD/AC, the company's high-energy Molecular Coincidence Detection upgrade package with attenuation correction capabilities. MCD/AC uses an external cesium-137 radioactive source to create an attenuation map of tissue densities in the body, and this map is used to compensate for artifacts created by tissue, bone, and other obstructions (SCAN 6/25/97).
MCD/AC improves the visualization of organs and structures deep in the body and could help extend coincidence detection from oncology applications into cardiology uses. MCD/AC received 510(k) clearance in October.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
